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Bronchoscopy is a procedure that is likely to provoke anxiety as the patient is surrounded by monitoring and
bronchoscopy equipment, and care is administered by strangers who perform intimate, invasive, and sometimes,
painful procedures. Sedation is needed, therefore, to allay anxiety and reduce stress, improve patient comfort and
co-operation, provide amnesia and facilitate the bronchoscopic procedure. In this review we try to summarize the
current knowledge on currently used sedation protocols with special reference to the commonly used
pharmacological agents. We believe sedation should be used routinely in fiberoptic bronchoscopy in order to
achieve a safe and pleasant procedure for both the patient and the pulmonologist.
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Sedation may be defined as a state of lessened functional
activity resulting in greater patient comfort, or ‘a state in
which pre-existing anxiety is removed or lessened or in
which signs of anxiety do not develop in circumstances in
which they would be expected to do so.’ (1). The
bronchoscopy suite is likely to provoke anxiety. The patient
is surrounded by monitoring and bronchoscopy equipment,
and care is administered by strangers who perform
intimate, invasive, often painful procedures. A recent study
(2) showed that most patients (62%) undergoing fiberoptic
bronchoscopy are anxious and fear pain and breathing
diculties that might be experienced during the procedure.
Explanations about the procedure and previous personal
experience of an endoscopic procedure had little impact on
allaying the fears of patients. In another study (3), fear of
the possible diagnosis of cancer, and dyspnoea or
asphyxiation was the main cause of anxiety in 68% of the
patients. Sedation may therefore allay anxiety and reduce
stress, improve patient comfort and co-operation, provide
amnesia and facilitate the bronchoscopic procedure. Since
in some cases repeated bronchoscopies are necessary,
achieving the above mentioned goals may increase the
willingness of patients to attend another bronchoscopy.
It is important to discriminate between sedation and
analgesia. As suggested by Sutherland (4), it is not the
awareness but the pain that makes the bronchoscopy soReceived 8 May 2000 and accepted in revised form 12 July 2000.
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the passage of the bronchoscope through the nose and to
some extent through the glottis area. Analgesics should
therefore be administered specifically to relieve pain. A
successful sedation regimen may augment methods of
analgesia by reducing the emotional component of pain.
It is therefore not surprising that sedation and analgesia are
often combined conceptually as they are intertwined
pharmacologically. Several studies confirm the common
practice of considering sedation with or without analgesia
for bronchoscopic procedures:
. In 1983, a postal survey (5) of bronchoscopic practice
in the United Kingdom indicated that of the 227
physicians performing fiberoptic bronchoscopy, only
6% did so without routinely using any sedative drugs.
Of the 103 physicians using a single drug, 78% gave
an opiate. Most of those using two drugs used an
opiate–benzodiazepine combination. There was no
association between overall complications and any
particular sedative combination.
. In 1989, a postal survey (6) of bronchoscopic practice
in North America indicated that of the 761 physicians
performing fiberoptic bronchoscopy, sedation was
used rarely by 24%, sometimes by 23% and
routinely by 51%. Midazolam and diazepam were
the most commonly used agents for fiberoptic
bronchoscopy.
. In 1992, results from a Scottish multi-centre
prospective study (7) of bronchoscopy indicated that
of the five centres participating in the study, only one
centre performed the procedure without sedation (5).
One centre routinely used general anaesthesia, and the
remaining routinely used intravenous phenoperidone# 2000 HARCOURT PUBLISHERS LTD
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pethidine.
. In 1997, a similar survey that was performed in Israel
(8) found that most centres used pethidine or
morphine i.m. and midazolam i.v. for sedation. One
centre used general anaesthesia and three centres
admitted the patients routinely to the ward for
bronchoscopy.
The necessity, however, for any sedation for fiberoptic
bronchoscopy has been questioned (9–10). Good patient
satisfaction has been reported where only local anaesthesia
was used with no sedation (9,11,12). Hatton et al. (9)
reported that although physicians found the procedure
easier with midazolam, the drug was not significantly better
than placebo in making patients comfortable or willing to
have the test repeated. Moreover, opiate sedation conferred
no advantage over placebo in patient perception of
comfort, but reduced willingness to have a repeat broncho-
scopy, a finding attributed to the dysphoric effects of
opiates and to the high incidence of nausea and vomiting
associated with these drugs. Nevertheless, these studies
were criticised (10) for the lack of objective assessment of
sedation—like the Ramsay score (14)—to titrate the level of
sedation (Table 1). In fact, as suggested by Parker et al.
(10), the failure of physicians to identify whether active
treatment had been given suggests that many patients were
not sedated. The dose of midazolam used in Hatton’s study
(9) was 0?07mgkg71. Williams et al. (15) showed that when
higher (0?24mg kg71) doses of midazolam were adminis-
tered, complete amnesia was achieved and only one of the
123 patients was not prepared to have the procedure
repeated.
Bronchoscopy is a brief procedure often performed on an
outpatient basis and, except for the use of very short-acting
drugs, routine use of sedation may prolong hospital stay
and increase the cost related to the procedure. Although
sedation may facilitate the bronchoscopist’s work, the
patient should be involved in whether they wish to have
sedation. Sedation can be administered only in units in
which the medical team has had specific training, monitor-
ing and resuscitation facilities are available, as well as
continuous nursing supervision for those patients who take
time to wake up.TABLE 1. Ramsay sedation levels (14)
Level Description
Awake
1 Patient anxious and agitated or restless or both
2 Patient co-operative, oriented, tranquil
3 Patients responds to commands only
Asleep Dependent on the patient’s response to light
glabellar tap or loud auditory stimulus
4 Brisk response
5 Sluggish response
6 No responseAgents for premedication and
sedation during bronchoscopy
There is a wide choice of sedative drugs and drug
combinations routinely used by bronchoscopists (Table 2).
The intent of this section is to be a comprehensive review of
some of the agents used for sedation in an outpatient setting
of fiberoptic bronchoscopy. Only agents that have been
evaluated are included in this review: topical lidocaine for
local anaesthesia; anti-cholinergic drugs for reducing
secretion, inhibition of vasovagal responses and for
bronchodilation; codeine phosphate for its anti-tussive
properties; benzodiazepines for sedation–hypnosis, anxio-
lysis and amnesia; propofol for sedation–hypnosis; opioids
for analgesia; clonidine for sedation, improving haemody-
namic stability and reducing the requirements for other
sedating agents. In addition, the benzodiazepine’s and
opiate’s antagonists, flumazenil and naloxone, respectively,
are discussed. These two antagonists should be readily
available in every bronchology unit in which sedation is
provided.
TOPICAL ANAESTHESIA
Most centres use direct application of local anaesthetics on
mucous membranes during fiberoptic bronchoscopy (15–
19). Lidocaine 2–10%, benzocaine (20%), tetracaine (1%),
and cocaine (4%) are commonly used.
Lidocaine is the most commonly used local anaesthetic
for fiberoptic bronchoscopy. It is short-acting, has a wide
margin of safety and tissue toxicity is rare. When applied on
mucous membranes in the upper airway, peak serum
lidocaine concentrations are 25–50% lower than if the
same dose had been given intravenously. However, the
administration of lidocaine solution to the lower bronchial
tree may result in significant serum concentrations (61). A
recent study (62) confirmed the safety of lidocaine
administered at a dose that did not exceed 7mg kg71.
Central nervous system and cardiac toxicity should be
expected only when higher doses are used. Lidocaine can be
sprayed onto the tongue, oropharynx and pharynx, and can
be applied directly through the bronchoscope to the
visualized glottis. Nebulization can also be used just prior
to the procedure. Superior laryngeal nerve block and
transtracheal anaesthesia (through the cricothyroid mem-
brane) are very effective but are rarely used today in most
centres.
Intravenous lidocaine has also been shown to prevent
cough as well as to reduce bronchial hyperreactivity (15).
Systemic side-effects, however, may occur.
Aerosolized benzocaine (20% solution) was commonly
used in the past but its action is short. Tetracaine (1%) and
cocaine (4%) are seldom used due to toxicity of the first and
the possible addictive effect of the latter.
ANTI-CHOLINERGIC DRUGS
Routine use of anti-cholinergic drugs as premedication for
fiberoptic bronchoscopy is generally recommended to dry
TABLE 2. Common pharmacological agents used for fiberoptic bronchoscopy
Agent Dose and route Onset Duration Effect Side-effects
Anti-cholinergic
Atropin i.m. 0?4–1mg 30–60min Variable Reduce secretion,
reduce vagal tone
Tachycardia, tachydysrhythmias,
AV dissociation, urinary retention,
dry mouth
Local anaesthetics
Lidocaine 1–10%, topical or
by inhalation.
Maximum dose 5–7mg kg71
5–10min 30–60min Cough suppression,
local anesthesia
Early bronchospasm, dizziness,
seizures in high dose. Toxic
reactions when plasma levels
exceed 5 mgml71.
Sedation
Midazolam i.v. 2?5–10mg
(0?05–0?075mgkg71)
1–3min 2 h Amnesia, sedation Respiratory depression
Diazepam i.v. 2–7mg
(0?1mg kg71) p.o. 5–10mg
1–3min
15–30min
2–8 h Amnesia, sedation Respiratory depression,
thrombophlebitis, pain
on injection
Narcotics
Meperidine i.v./i.m. 20–75mg (1mgkg71) i.v. 1–3min
i.m. 15–30min
2–4 h Analgesia Respiratory depression,
nausea
Codeine i.m. 20–120mg 30min 2–4 h Cough suppression Urinary retention
Morphine i.v./i.m. 2–10mg (0?1mgkg71) i.v. 5min
i.m.15–30min
2–6 h Analgesia Respiratory depression,
nausea, itching, bronchospasm,
bradycardia, biliary spasm
Fentanyl i.v. 50–100 mg (1 mg kg71) 2min 30–60min Analgesia Respiratory depression, nausea,
chest wall rigidity, bradycardia
Alfentanil i.v. 250–1000 mg (10 mg kg71) 1min 15–30min Analgesia Respiratory depression, nausea,
chest wall rigidity
Propofol i.v. 50 mg kg71min71 (10–30mg) 30 sec 8–10min Sedation Respiratory depression, hypotension
Antagonists
Naloxone i.v. 40–40 0 mg titrated to
effect q 2–3min
1min Dose dependent,
lasting 20–60min
Reversal of
opioid effect
Tachycardia, hypertension,
dysrhythmias
Flumazenil 0?4–1mg 2min 1 h Reversal of
benzodiazepine
effect
CNS excitation, nausea,
residual sedation
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1148 I. MATOT AND M. R. KRAMERsecretions and to prevent bradycardia and bronchoconstric-
tion (25,26). Until recently it was regarded as a standard
preparation for the procedure (5,6,23,24). Several studies
have questioned the use of prebronchoscopy atropine. In a
group of patients who did not receive atropine, broncho-
scopy was safely and eciently carried out (12,25). In
particular, after performing more than 1000 bronchoscopies
without atropine premedication, Makker et al. (26) did not
note any excessive secretions or bradycardia. A recent study
(27) reported that atropine premedication was not of clinical
benefit compared to placebo when parameters of broncho-
dilation, secretions, tracheo-bronchial bleeding, desaturation
and arrhythmias were investigated. Moreover, atropine
premedication might cause dry mouth, blurred vision,
glaucoma or tachycardia. Since myocardial ischaemia has
been reported to occur during the procedure (28), tachy-
cardia should be avoided and therefore the routine admin-
istration of prebronchoscopy atropine should be
reconsidered.
Other agents such as scopolamine and glycopyrrolate
may also be used as drying agents. These agents, however,
may cause disorientation (scopolamine) and urinary reten-
tion (glycopyrrolate). Today, in many centres, these agents
have been abandoned.
CODEINE PHOSPHATE
Codeine phosphate has an anti-tussive effect in patients
undergoing bronchoscopy under light local anaesthesia and
midazolam sedation (29). Codeine (20–120mg) can be given
orally or intra-muscularly as a premedication. In patients
who received codeine (oral, 0?4mgkg71) 60min before
bronchoscopy, the dose of supplemental local anaesthetic
requirements and the degree of desaturation were signifi-
cantly lower compared to placebo (30).
BENZODIAZEPINES
The three benzodiazepines (lorazepam, diazepam and
midazolam) are commonly used as premedication and
sedative agents for bronchoscopy (24,25,31,32). These
drugs provide anxiolysis, sedation, hypnosis and amnesia.
When used alone they have limited effects on cardio-
respiratory function. However, very often these agents are
combined with opioids, which potentiates the respiratory
depression effects of both classes of agents (24,25,30,31).
Lorazepam (32) may be given either intravenously or
orally. It is approximately four times as potent as
diazepam. The onset of action is slower and the duration
of action is longer with lorazepam. Unlike diazepam,
lorazepam is not transformed to a pharmacologically active
metabolite. The ecacy of oral lorazepam (2mg) as
premedication for bronchoscopy has been evaluated by
Maltais et al. (32). Although patient’s co-operation during
the procedure and immediate patients’ perception of the
bronchoscopy were not significantly improved, the patient’s
final impression (24 h later) was more favourable with the
use of lorazepam. Most patients who received placebo
(65?3%) described the procedure as dicult, compared to38% of the patients in the lorazepam group. The authors
attributed this finding to the anterograde amnestic effect of
lorazepam. No adverse effect was noted with this sedative
regimen and patients were able to leave the bronchology
unit 30min after the procedure.
Diazepam (33) has a relatively protracted duration of
action related to both the parent compound and, more
importantly, active metabolites produced following hepatic
metabolism. Moreover, diazepam is diluted in propylene
glycol solution, which produces pain on injection and high
incidence of thrombophlebitis. The potency of diazepam
for sedation seems to be about 50% to 25% that of
midazolam. For an adult weighting 70 kg, intravenous
injection of 10–20mg of diazepam provides effective
sedation. This dose should be reduced by 10% per decade
(20 years old and above). Oral administration requires at
least 1 h before the onset of measurable sedative or
anxiolytic effects. A randomized trial (34) comparing
intravenous diazepam (10mg) with saline after intramus-
cular atropine reported that both bronchoscopist and
patients noted a significant sedative effect and fewer
coughs with diazepam. Recently, Putinati et al. (25) found,
in 100 patients undergoing diagnostic bronchoscopy, that
tolerance to the procedure was better in patients sedated
with intravenous diazepam compared to non-sedated
patients. The tolerance score was much lower when rated
by patients than by the bronchoscopist. This might high-
light, as the authors suggested, the under-estimation of
patient’s discomfort by the bronchoscopist. The availability
of a shorter-acting, water-soluble anxiolytic such as
midazolam has decreased dramatically the popularity of
diazepam.
Midazolam (35) is a water-soluble, short-acting benzo-
diazepine that does not produce pain or thrombophlebitis
on injection. The metabolites of midazolam have negligible
effects. It provides profound procedural amnesia and
sedation, and since it can be given by various routes (oral,
intramuscular, intravenous), it is now used extensively for
sedation in outpatient bronchoscopy. Administration of
midazolam for premedication should be taken cautiously in
the elderly, who are more sensitive to sedation. The dose
must therefore be tailored to each patient: 0?07–
0?15mgkg71 midazolam usually provides effective sedation
in young patients. Sedation is effective for 20– 40min.
Williams et al. (27) reported the use of high dose
(0?24mgkg71) intravenous midazolam for sedation during
fiberoptic bronchoscopy. Although this dose provided total
amnesia, it took a long time for the patients to wake up and
to be discharged (on average 1 h and 2?5 h, respectively).
Moreover, 9?8% of the patients required flumazenil to
reverse the effects of midazolam. In a subsequent study,
Williams et al. (34) reported 2 years of experience with
midazolam sedation for bronchoscopy. Midazolam was
administered intravenously over several minutes till the
patient was judged to be lightly asleep. The mean dose of
midazolam used was 0?16mgkg71. Patients took 1 h to
wake up and 8% were given flumazenil to reverse sedation.
Only nine patients (total 337 patients) had some memory of
the procedure. Similar doses of midazolam were used in
other studies (27,29,35).
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for the benzodiazepines receptors (36), may be used to
reverse respiratory depression and haemodynamic effects of
the benzodiazepines. It must be administered by repeated
bolus injections or continuous infusion because of its short
duration of action. Patients may become obtunded later
when the flumazenil wears off. For this reason, the use of
flumazenil requires an extended observation period before a
patient can be declared no longer under the influence of the
benzodiazepines. Flumazenil has been given in large oral
and intravenous doses with remarkably few toxic reactions.
Recently (37), flumazenil (0?1– 0?2mg in incremental doses)
has been shown to be safe and effective in aiding recovery
from diazepam-facilitated bronchoscopy. Patients in the
flumazenil group showed significantly greater proficiency
with psychometric tests. The importance of flumazenil in
reducing the risk of respiratory depression and hypoxia
during benzodiazepine-facilitated bronchoscopy cannot be
overstated.
PROPOFOL
Propofol (31), an alkyl-phenol, is a sedative–hypnotic agent
that has a rapid onset and short duration of action. It
produces a dose-dependent level of sedation, varying from
conscious sedation to general anaesthesia. It is only
available for intravenous administration. Propofol by
continuous infusion provides a readily titratable level of
sedation and a rapid recovery once infusion is terminated,
without the need for expensive antagonist agents. From a
clinical point of view, it is necessary to acquire experience to
adjust the dosage of propofol to the individual patient,
since there is a wide variability in the response of the
patients to the drug (38). Two studies (35,39) compared
midazolam with propofol for sedation in outpatient
bronchoscopy and reported that propofol allowed faster
onset of action and recovery than midazolam. Also,
memory and motor reaction times did not differ from
baseline in the propofol group, but were significantly
impaired in the midazolam group 60min after the end of
the procedure (32). Incidence of oxygen desaturation and
the level of patient’s satisfaction were comparable between
the groups.
OPIATES
Because benzodiazepines and propofol provide only seda-
tion and amnesia and have little, if any, analgesic effects,
they are often used in conjunction with opioids. A common
side-effect of all these agents is respiratory depression, the
risk of which increases with the dose and the rate of
administration, and with the co-administration of sedative
agents (40). Other common side-effects of opiates include
nausea, vomiting, urinary retention, chest wall rigidity,
mental clouding, dysphoria and pruritus. Because broncho-
scopy frequently lasts less than 30min, the long-acting
opioids (morphine and meperidine) do not seem to be ideal
drugs for providing analgesia during the procedure. These
agents might leave the patient at risk for adverse effectssuch as respiratory depression for a significant period of
time. Other shorter acting opioids such as fentanyl,
alfentanil or remifentanil should therefore be considered.
Several opioids have been used for analgesia during
outpatient bronchoscopy. A study (25) that compared
midazolam, alfentanil and a combination of both for
sedation for fiberoptic bronchoscopy found that there was
significantly less cough, and the need for additional
lignocaine was significantly less, in patients treated with
alfentanil compared to the other two groups. In addition,
those who received the combination of midazolam and
alfentanil had a greater drop in oxygen saturation when
compared with each drug given alone. In this study the
average duration of procedure was very short (*6min) and
the average dose of midazolam and alfentanil used was
5mg and 0?6mg, respectively. A significant reduction in
cough count was also noted with alfentanil sedation when
compared with diazepam and papaveretum (41). The level
of discomfort was not significantly different between the
two groups. In a prospective, randomized study (42), we
compared sedation for fiberoptic bronchoscopy provided
by alfentanil–propofol with meperidine–midazolam. These
two methods were compared in terms of haemodynamics,
frequency of desaturation, bronchoscopist acceptability
and patient comfort. Significant elevations in blood
pressures were observed only in patients sedated with
meperidine–midazolam. There were no significant differ-
ences between the two groups in oxygen desaturation
episodes or in the mean lowest oxygen saturation. The
results of the questionnaire completed by the patients and
the bronchoscopist indicated similar levels of satisfaction in
each group. We concluded that compared to sedation with
alfentanil–propofol, sedation with meperidine–midazolam
gives equally good operating conditions, provides compar-
able levels of patient’s comfort and satisfaction, produces
satisfactory amnesia, and is safe. Since alfentanil–propofol
sedation attenuated the blood pressure response, this
regimen might be a more appropriate technique for use in
‘high risk’ cardiac patients. The combination of midazolam
and alfentanil, however, has not been evaluated.
Naloxone (40), the opioid antagonist, may be used to
restore ventilation in patients who breathe inadequately
after opioid overdose. The administration of naloxone,
however, may be accompanied by significant side-effects.
Naloxone can cause nausea, hypertension, arrhythmias and
acute pulmonary oedema, and therefore opioid reversal is
best avoided in patients in whom increases in blood
pressure and heart rate could be detrimental, i.e. patients
with coronary artery disease or cerebrovascular disease,
patients with pheochromocytoma or with chroman tissue
tumours. Onset of action after intravenous administration
of naloxone is rapid (1–2min) and the half-life and duration
of effect are short. Attempts to compensate for naloxone’s
short duration of action by increasing the dose risked
increasing the incidence and severity of unwanted side-
effects. Most often, titration to effect in 0?5–1 mg kg71
boluses every 2–3min will restore adequate spontaneous
ventilation. Recurrence of respiratory depression after
naloxone is due in part to the agent’s short half-life.
Patients therefore should be held under the supervision of
1150 I. MATOT AND M. R. KRAMERtrained nursing staff. Because short-lasting opioids (alfen-
tanil, remifentanil) rarely pose a danger of renarcotization,
these agents seem to be the most appropriate agents to use
when analgesia is needed for short procedures such as
bronchoscopy.
CLONIDINE
The centrally acting a2-agonist clonidine attenuates stress-
induced sympathoadrenal responses to painful stimuli,
improves intra-operative haemodynamic stability, reduces
the incidence of perioperative myocardial ischaemic epi-
sodes in patients with suspected or documented coronary
artery disease and decreases anaesthetic requirements during
surgery (43–47). Moreover, clonidine has also been found to
blunt the stress response to endotracheal intubation (48–50).
Therefore, oral clonidine seems well suited as premedication
for fiberoptic bronchoscopy. Recently, we evaluated (51) the
effects of chlonidine (orally, 150 to 300mg) premedication on
alterations of blood pressure, heart rate, and oxygen
saturation during fiberoptic bronchoscopy in a randomized,
double-blind, placebo-controlled study. Significant increases
in blood pressure and heart rate were observed only in the
control group. Clonidine 150mg blunted the haemodynamic
response to fiberoptic bronchoscopy. Significant reductions
in systolic blood pressure (5 90mmHg) were observed in all
patients premedicated with 300mg clonidine. Incidence of
oxygen desaturation was comparable between the groups.
We concluded that premedication with 150 mg oral clonidine
attenuates haemodynamic responses to fiberoptic broncho-
scopy, without causing excessive haemodynamic depression
and sedation. Since cardiac arrhythmias and myocardial
ischaemia may develop during the procedure (28,52,53),
these data encourage the administration of clonidine as
premedication in patients undergoing fiberoptic broncho-
scopy, particularly in those with, or at risk for coronary
artery disease.
Monitoring during bronchoscopy
Although the morbidity and mortality associated with
fiberoptic bronchoscopy are low, cardiac arrhythmias, as
well as ischaemic episodes, have been reported to occur
during the procedure in up to 70% and 17% of the patients,
respectively (28,52,53). The usual haemodynamic response
to bronchoscopy includes an increase in heart rate and
blood pressure along with episodes of oxygen desaturation
(42,51,54–56). In addition, with the introduction of seda-
tion, hypercapnea may develop due to alveolar hypoventila-
tion (57). These changes may lead to an imbalance between
myocardial oxygen demand and delivery, which could result
in arrhythmias, myocardial ischaemia and eventual infarc-
tion (58), especially in patients with clinical or silent
coronary artery disease, hypertension and those with
accompanying lung disease. Such patients are frequent
among those who present for fiberoptic bronchoscopy.
Patients should therefore be monitored routinely with
electrocardiogram, an automated non-invasive blood pres-
sure device and pulse oximeter. In addition, resuscitationequipment for both airway management [nasal and oral
airways, anaesthesia masks, laryngoscope and blades,
endotracheal tubes, intubating stylets, self-inflating (Ambu)
bag, suction] and cardiac emergencies [defibrillator and
drugs (epinephrine, lidocaine, bretylium tosylate, procai-
neamide, sodium bicarbonate, calcium chloride and atro-
pine as well as sodium thiopental, succinylcholine and
reversal agents)], must be readily available in the broncho-
scopy suit.
Reductions in oxygen saturation are recognized in
patients undergoing bronchoscopy. We documented (49)
desaturation in 30% of the patients undergoing broncho-
scopy under alfentanil–propofol or meperidine–midazolam
sedation, despite supplemental oxygen. Others (35,39,41)
also reported desaturation episodes. In another study (39),
median least oxygen saturation was 83% and 86% in the
propofol and midazolam groups, respectively. These data
emphasize the need for the routine use of pulse oximetry
and supplemental oxygen administration during fiberoptic
bronchoscopy. Recently (56), oxygenation via a pharyngeal
catheter was found to be superior to nasal catheter to
prevent hypoxaemia.
Hypercapnea may remain undetected by pulse oximetry
and may lead to respiratory arrest, hypertension and
cardiac arrhythmias. A recent study (57) showed that
transcutaneous monitoring of PCO2 provided evidence of
hypoventilation during fiberoptic bronchoscopy.
Previous studies that evaluated different drugs for
sedation did not use a recognized objective assessment of
sedation to titrate the level of sedation. Investigators aimed
for ‘light sedation’ or ‘heavy sedation’ by drug titration
(9,21,24,27,34,35,41,57). Nowadays, several sedation-scoring
systems have been developed to assist clinicians in determining
the effectiveness of sedation. The commonest sedation score in
daily use in the Ramsay score (13) (Table 1), but several others
are also popular (59,60). Regardless of the scoring system
used, the best assessment is continued observation of patient
responsiveness. An evaluation of patient’s status should be
performed every 2–3min during the procedure and should be
assessed into recovery. As the clinician performing the
bronchoscopy is not in a position to monitor the patient, an
experienced healthcare professional should be responsible for
monitoring the patient’s status during the procedure. This is
usually the responsibility of a registered nurse with special
experience or training in sedation.
Care of the patient does not end when the procedure is
completed. As the patient moves from the periprocedure
area to the recovery area, monitoring of the patient must
remain paramount for at least 30–60min. During the
recovery phase the patient should return to a preprocedure
baseline of mental acuity, while keeping airway patency and
protective reflexes, haemodynamic stability, and ambula-
tory and gait status. Only then can the patient be
discharged home with minimal risk of complications.
Is there an ‘ideal’ sedation?
This review presents the reader with certain options and
recommendations for the application of sedation in patients
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on the level of intervention (ranging from bronchoscopic
airway examination to laser bronchoscopy and stenting),
and human resources available in the bronchoscopic unit
(nurses, assistants and anaesthesiologist), the clinician must
make the decision as to whether intravenous sedation will
be sucient or if a deeper or general anaesthesia will be
needed.
Currently, there is no such thing as ‘ideal sedation’ for
fiberoptic bronchoscopy. We find that the i.v. administra-
tion of midazolam (in incremental doses of 2mg) and
alfentanil (for short procedures, 10mg kg71) or pethidine
(for longer procedures, 1mgkg71) provides excellent
operating conditions, produces satisfactory amnesia as well
as patient’s comfort, and is safe. This is supplemented with
pre-procedural application of topical anaesthesia (lidocain
2–10%) of the airway. Premedication is required only in
patients at risk for ischaemic heart disease and consists of
oral clonidine 150 mg, which is given to the patients 90min
before the procedure. We currently do not use atropin.
Complicated procedures
The current licensing requirement in most countries to have
propofol administered and monitored by an anaesthetist,
and the higher cost of propofol, makes sedation with
midazolam preferable. Propofol, however, is an excellent
drug and should therefore be reserved for complicated
bronchoscopies (such as prolonged laser therapies, stents
placements, etc.), in which general anaesthesia is required
with or without maintenance of spontaneous ventilation, or
for patients who became agitated and restless after the
administration of midazolam. In the latter group of
patients (unco-operative ones), another option which will
usually suce is the intra-muscular administration of
ketamine (3–5mg kg71) with midazolam (2mg, to negate
the hallucinogenic effect of ketamine). Oral secretions are
markedly stimulated by ketamine, and therefore co-admin-
istration of anti-sialagogue such as atropin is recommended
in these cases.
Summary
Several requirements must be met for the ideal sedation
during day-care bronchoscopy. Firstly, it has to be both
effective and safe. Furthermore, it should be easy to
administer and monitor, short-acting and readily reversible.
It should leave the patient with fewest side-effects while
providing adequate analgesia and amnesia, without sedat-
ing to the point of airway compromise.
Although sedation today is quite satisfactory for both the
patients and the pulmonologists, further studies are required
to find the ‘ideal sedation’ for fiberoptic bronchoscopy.
References
1. Norris W. The quantitative assessment of premedica-
tion. Br J Anaesth 1969; 41: 778–784.2. Poi PJH, Chuah SY, Srinivas P, Liam CK. Common
fears of patients undergoing bronchoscopy. Eur Repir J
1998; 11: 1147–1149.
3. Mendes de Leon C, Bezel R, Karrer W, Brandil O.
Premedication in fibre-optic bronchoscopy from the
patient’s and the physician’s viewpoint: a randomized
study for the comparison of midazolam and hydro-
codone. Schweiz Med Wochenschr 1986; 116:
1267–1272.
4. Sutherland FWH. Intravenous sedation is inappropri-
ate in most minor procedures. BMJ 1995; 310: 872.
5. Simpson FG, Arnold AG, Purvis A, et al. Postal survey
of bronchoscopic practice by physicians in the United
Kingdom. Thorax 1986; 41: 311–317.
6. Prakash UBS, Offord KP, Stubbs SE. Bronchoscopy in
North America: the ACCP survey. Chest 1991; 100:
1668–1675.
7. McLean AN, Semple PD’A, Franklin DH, Petrie G,
Millar EA, Douglas JG. The Scottish multi-centre
prospective study of bronchoscopy for bronchial
carcinoma and suggested audit standards. Repir Med
1998; 92: 1110–1115.
8. Kramer MR, Bublil M. Bronchoscopies in Israel: a
national survey. Harefua 1998; 134: 373–375.
9. Hatton MQF, Allen MB, Vathenen AS, Mellor E,
Cooke NJ. Does sedation help in fibre-optic broncho-
scopy. BMJ 1994; 309: 1206–1207.
10. Thomas G, McBeth C. Sedation in fibre-optic broncho-
scopy. BMJ 1995; 310: 872–873.
11. Allen MB. Sedation in fibre-optic bronchoscopy. BMJ
1995; 310: 1333.
12. Pearce SJ. Fibre-optic bronchoscopy: is sedation
necessary? BMJ 1980; 281: 779–780.
13. Colt HG, Morris JF. Fibre-optic bronchoscopy with-
out sedation: retrospective study. Chest 1990; 98:
1327–1330.
14. Ramsay MAE, Savege TM, Simpson BRJ, et al.
Controlled sedation with alphaxalone-alphadolone.
BMJ 1974; 2: 656–659.
15. Kilpatrik MB. Lidocaintopica anesthesia in FOB.
Chest 1989; 96: 965–968.
16. Foster WM, Hurewitz AN. Aerosolized lidocaine
reduces dose of topical anesthetic for bronchoscopy.
Am Rev Respir Dis 1992; 146: 520–522.
17. Bulut Y, Hirshman CA, Brown RH. Prevention of
lidocaine aerosol-induced bronchoconstriction with in-
travenous lidocaine. Anesthesiology 1996; 85: 853–859.
18. Groeben H, Silvanus MT, Beste M, Peters J. Both
intravenous and inhaled lidocaine attenuate reflex
bronchoconstriction but at different plasma concentra-
tions. Am J Respir Crit Care Med 1999; 159: 530–535.
19. Jakobsen CJ, Ahlburg P, Holdgarg HO, et al.
Comparison of intravenous and topical lidocaine as a
suppressant of coughing after bronchoscopy during
general anesthesia. Acta Anesthesiol Scand 1991; 35:
238–241.
20. Poulton TJ, James FM. Cough suppression by
lidocaine. Anesthesiology 1979; 50: 470–472.
21. Williams TJ, Nicoulet I, Coleman E, McAlaney C.
Safety and patient acceptability of intravenous
1152 I. MATOT AND M. R. KRAMERmidazolam for fibre-optic bronchoscopy. Respir Med
1994; 88: 305–307.
22. Zavala DC. Complications following fibre-optic
bronchoscopy: the ‘good news’ and the ‘bad news’
(editorial). Chest 1978; 73: 783–785.
23. Ereth MH, Stubbs SE, Lennon RL. Bronchoscopic
pharmacology and anesthesia. In: Prakash UBS, ed.
Bronchoscopy. New York: Raven Press, 1994: 91–104.
24. Greig JH, Cooper SM, Kasimbazi HJN, Monie RDH,
Fennerty AG, Watson B. Sedaton for fibre-optic
bronchoscopy. Respir Med 1995; 89: 53–56.
25. Putinati S,BallerinL,CorbettaL,TrevisaniL, PotenaA.
Patient satisfaction with conscious sedation for
bronchoscopy. Chest 1999; 115: 1437–1440.
26. Makker H, Kishen R, O’Driscoll R. Atropine as
premedication for bronchoscopy. Lancet 1995; 345:
724–725.
27. Williams T, Brooks T, Ward C. The role of atropine
premedication in fibre-optic bronchoscopy using in-
travenous midazolam sedation. Chest 1998; 113:
1394–1398.
28. Matot I, Kramer MR, Glantz L, Drenger B, Cotev S.
Incidence of myocardial ischemia in patients under-
going outpatient fibre-optic bronchoscopy. Chest 1997;
12: 1454–1458.
29. Tsunekuza Y, Sato H, Tsukioka T, Nakamura Y,
Watanabe Y. The role of codeine phosphate premedi-
cation in fibre-optic bronchoscopy under in sucient
local anaesthesia and midazolam sedation. Respir Med
1999; 93: 413–415.
30. Lichtor JL. Psychological preparation and preoperative
medication. In: Miller RD, ed. Anesthesia. Edinburgh:
Churchill Livingstone, 1990: 895–928.
31. Reeves JG, Glass PSA. Nonbarbiturate intravenous
anesthetics. In: Miller RD, ed. Anesthesia. Edinburgh:
Churchill Livingstone, 1990: 243–279.
32. Maltais F, Laberge F, Laviolette M. A randomized,
double-blind, placebo-controlled study of lorazepam as
premedication for bronchoscopy. Chest 1996; 109:
1195–1198.
33. Rees PJ, Hay JG, Webb JR. Premedication for fibre-
optic bronchoscopy. Thorax 1983; 38: 624–627.
34. Williams TJ, Bowie PE. Midazolam sedation to
produce complete amnesia for bronchoscopy: 2 years’
experience at a district general hospital. Respir Med
1999; 93: 361–365.
35. Clarkson K, Power CK, O’Connel F, Pathmakanthan
Sh, Burke CM. A comparative evaluation of propofol
and midazolam as sedative agents in fibre-optic
bronchoscopy. Chest 1993; 104: 1029–1031.
36. Hoffman EJ, Warren EW. Flumazenil: a benzodiaze-
pine antagonist. Clin Pharm 1993; 12: 641–665.
37. Williamson BH, Nolan PJ, Tribe AE, Thompson PJ. A
placebo controlled study of flumazenil in bronchoscopic
procedures. Br J Clin Pharmacol 1997; 43: 77–83.
38. Smith I, White PF, Nathanson M, Gouldson R.
Propofol. An update on its clinical use. Anesthesiology
1994; 81: 1005–1043.
39. Crawford M, Pollock J, Anderson K, Glavin RJ,
Macintyre D, Vernon D. Comparison of midazolamwith propofol for sedation in outpatient bronchoscopy.
Br J Anaesth 1993; 70: 419–422.
40. Bailey PL, Stanley TH. Narcotic intravenous anes-
thetics. In: Miller RD, ed. Anesthesia. Edinburgh:
Churchill Livingstone, 1990: 281–366.
41. Webb AR, Doherty JF, Chester MR, Cummin RC,
Woodhead MA, Nanson EM, Flack ST, Millard FJC.
Sedation for fibre-optic bronchoscopy; comparison of
alfentanil, papaveretum, and diazepam. Respir Med
1989; 198: 215–217.
42. Matot I, Kramer MR. Sedation for fibre-optic
bronchoscopy: alfentanil-propofol vs pethidine-mida-
zolam. J Bronchol 1999; 6: 74–77.
43. Salonen MA, Kanto JH, Maze M. Clinical interactions
with alpha2 adrenergic agonists in anesthetic practice. J
Clin Anesth 1992; 4: 164–172.
44. Aantaa R, Scheinin M. Alpha-2 adrenergic agents
in anaesthesia. Acta Anaesthesiol Scand 1993; 37:
433–448.
45. Longnecker DE. Alpine anesthesia: Can pretreatment
with clonidine decrease the peaks and valleys? Anesthe-
siology 1987; 67: 1–2.
46. Stuhmeier KD, Mainzer B, Cierpka J, Sandmann W,
Tarnow J. Small, oral dose of clonidine reduces the
incidence of intraoperative myocardial ischemia in
patients having vascular surgery. Anesthesiology 1996;
85: 706–712.
47. Ghignone M, Noe C, Calvillo O, Quintin L. Anesthesia
for ophthalmic surgery in the elderly: the effects of
clonidine on intraocular pressure, perioperative hemo-
dynamics, and anesthetic requirement. Anesthesiology
1988; 68: 707–716.
48. Zalunardo MP, Zollinger A, Spahn DR, et al.
Effect of intravenous and oral clonidine on hemody-
namic and plasma-catecholamine response due to
endotracheal intubation. J Clin Anesth 1997; 9:
143–147.
49. GhignoneN,QuintinL,DukePC,KehlerCH,CalvilloO.
Effect of clonidine on narcotic requirements and
hemodynamic response during induction of fentanyl
anesthesia and endotracheal intubation. Anesthesiology
1986; 64: 36–42.
50. Orko R, Pouttu J, Ghighone M, Rosenberg PH. Effect
of clonidine on hemodynamic responses to endotra-
cheal intubation and gastric acidity. Acta Anesthesiol
Scand 1987; 31: 325–329.
51. Matot I, Kuras Y, Kramer MR. Effect of clonidine
premedication on hemodynamic responses to fibre-
optic bronchoscopy. Anesthesia 2000; 55: 269–274.
52. Elguindi AS, Harrison GH, Abdulla AM, et al. Cardiac
rhythm disturbances during fibre-optic bronchoscopy:
a prospective study. J Thorac Cardiovasc Surg 1979; 77:
557–561.
53. Katz AS, Michelson EL, Stawicki J, et al. Cardiac
arrhythmias. Frequency during fibre-optic broncho-
scopy and correlation with hypoxemia. Arch Intern
Med 1981; 141 :603–606.
54. Lundgren R, Haggmark S, Reiz S. Hemodynamic
effects of flexible fibre-optic bronchoscopy performed
under topical anesthesia. Chest 1982; 82: 295–299.
SEDATION IN OUTPATIENT BRONCHOSCOPY 115355. Dubrawsky C, Awe RJ, Jenkins DE. The effect of
bronchofiberscopic examination on oxygenation status.
Chest 1975; 67: 137–140.
56. Milman N, Faurschou P, Grode G, et al. Pulse
oximetry during fibre-optic bronchoscopy in local
anaesthesia: frequency of hypoxaemia and effect of
oxygen supplementation. Respiration 1994; 61:
342–347.
57. Evans EN, Ganeshalingam K, Ebden P. Changes in
oxygen saturation and transcutaneous carbon dioxide
and oxygen levels in patients undergoing fibre-optic
bronchoscopy. Respir Med 1998; 92: 739–742.
58. Fleisher LA. Perioperative Myocardial ischemia and
infarction. Intern Anesth Clin 1994; 4: 1–15.59. Chernik DA, Gillings D, Laine H. Validity and
reliability of the observer’s assessment/sedation scale:
Study with intravenous midazolam. J Clin Psychophar-
macol 1990; 10: 244–251.
60. Clarck BA. A new approach to assessment and
documentation of conscious sedation during endoscopic
examinations. Gastroenterol Nurs 1994; 16: 199–203.
61. Efthimiou J, Higenbottam T, Holt D, Cochrane GM.
Plasma concentrations of lignocaine during fibre-optic
bronchoscopy. Thorax 1982; 37: 68–71.
62. Milman N, Laub M, Munch EP, Angelo HR. Serum
concentratins of lignocaine and its metabolite mono-
ethylglycinexylidide during fibre-optic bronchoscopy
on local anesthesia. Respir Med 1998; 92: 40–43.
